nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—type 1 diabetes mellitus	0.6	1	CbGaD
Naloxone—CREB1—nerve—type 1 diabetes mellitus	0.00951	0.18	CbGeAlD
Naloxone—OPRM1—nerve—type 1 diabetes mellitus	0.00513	0.0968	CbGeAlD
Naloxone—CREB1—islet of Langerhans—type 1 diabetes mellitus	0.00461	0.087	CbGeAlD
Naloxone—CREB1—retina—type 1 diabetes mellitus	0.00394	0.0744	CbGeAlD
Naloxone—CREB1—nephron tubule—type 1 diabetes mellitus	0.00371	0.0701	CbGeAlD
Naloxone—CREB1—cardiovascular system—type 1 diabetes mellitus	0.00333	0.0629	CbGeAlD
Naloxone—CREB1—kidney—type 1 diabetes mellitus	0.00326	0.0616	CbGeAlD
Naloxone—CREB1—pancreas—type 1 diabetes mellitus	0.00324	0.0612	CbGeAlD
Naloxone—CREB1—lymphoid tissue—type 1 diabetes mellitus	0.0028	0.0529	CbGeAlD
Naloxone—OPRD1—kidney—type 1 diabetes mellitus	0.00258	0.0487	CbGeAlD
Naloxone—SLCO1A2—kidney—type 1 diabetes mellitus	0.00151	0.0286	CbGeAlD
Naloxone—ESR1—cardiovascular system—type 1 diabetes mellitus	0.00131	0.0248	CbGeAlD
Naloxone—ESR1—kidney—type 1 diabetes mellitus	0.00128	0.0242	CbGeAlD
Naloxone—ESR1—lymphoid tissue—type 1 diabetes mellitus	0.0011	0.0208	CbGeAlD
Naloxone—CYP2C8—kidney—type 1 diabetes mellitus	0.00106	0.02	CbGeAlD
Naloxone—ABCB1—islet of Langerhans—type 1 diabetes mellitus	0.000716	0.0135	CbGeAlD
Naloxone—CYP3A4—kidney—type 1 diabetes mellitus	0.000716	0.0135	CbGeAlD
Naloxone—ABCB1—retina—type 1 diabetes mellitus	0.000613	0.0116	CbGeAlD
Naloxone—ABCB1—nephron tubule—type 1 diabetes mellitus	0.000577	0.0109	CbGeAlD
Naloxone—ABCB1—cardiovascular system—type 1 diabetes mellitus	0.000518	0.00978	CbGeAlD
Naloxone—ABCB1—kidney—type 1 diabetes mellitus	0.000507	0.00957	CbGeAlD
Naloxone—ABCB1—pancreas—type 1 diabetes mellitus	0.000504	0.00951	CbGeAlD
Naloxone—ABCB1—lymphoid tissue—type 1 diabetes mellitus	0.000435	0.00822	CbGeAlD
Naloxone—OPRD1—Signaling Pathways—SST—type 1 diabetes mellitus	5.72e-05	0.000165	CbGpPWpGaD
Naloxone—ALB—Metabolism—G6PC2—type 1 diabetes mellitus	5.72e-05	0.000165	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ADRB1—type 1 diabetes mellitus	5.72e-05	0.000165	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APOC3—type 1 diabetes mellitus	5.72e-05	0.000165	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IAPP—type 1 diabetes mellitus	5.72e-05	0.000165	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ADRB1—type 1 diabetes mellitus	5.7e-05	0.000164	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL2RA—type 1 diabetes mellitus	5.64e-05	0.000163	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VAV1—type 1 diabetes mellitus	5.58e-05	0.000161	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-A—type 1 diabetes mellitus	5.58e-05	0.000161	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL6—type 1 diabetes mellitus	5.57e-05	0.00016	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GAL—type 1 diabetes mellitus	5.49e-05	0.000158	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CCR5—type 1 diabetes mellitus	5.48e-05	0.000158	CbGpPWpGaD
Naloxone—SLCO1A2—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	5.45e-05	0.000157	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL20—type 1 diabetes mellitus	5.43e-05	0.000156	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL11—type 1 diabetes mellitus	5.43e-05	0.000156	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—STAT3—type 1 diabetes mellitus	5.41e-05	0.000156	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL2RA—type 1 diabetes mellitus	5.4e-05	0.000155	CbGpPWpGaD
Naloxone—CREB1—Disease—ERBB3—type 1 diabetes mellitus	5.37e-05	0.000155	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HBA2—type 1 diabetes mellitus	5.33e-05	0.000154	CbGpPWpGaD
Naloxone—CREB1—Immune System—CRP—type 1 diabetes mellitus	5.32e-05	0.000153	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—IL6—type 1 diabetes mellitus	5.3e-05	0.000153	CbGpPWpGaD
Naloxone—CREB1—Disease—CCR5—type 1 diabetes mellitus	5.28e-05	0.000152	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ITPR3—type 1 diabetes mellitus	5.17e-05	0.000149	CbGpPWpGaD
Naloxone—CREB1—Disease—HLA-A—type 1 diabetes mellitus	5.15e-05	0.000148	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—GCG—type 1 diabetes mellitus	5.12e-05	0.000147	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—GCG—type 1 diabetes mellitus	5.1e-05	0.000147	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CHRM2—type 1 diabetes mellitus	5.1e-05	0.000147	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CCR5—type 1 diabetes mellitus	5.1e-05	0.000147	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-DRB1—type 1 diabetes mellitus	5.1e-05	0.000147	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IGF2—type 1 diabetes mellitus	5.06e-05	0.000146	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2RA—type 1 diabetes mellitus	5.02e-05	0.000145	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SST—type 1 diabetes mellitus	5.02e-05	0.000145	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—G6PC2—type 1 diabetes mellitus	5.01e-05	0.000144	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ADRB1—type 1 diabetes mellitus	5e-05	0.000144	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ABCC8—type 1 diabetes mellitus	4.99e-05	0.000144	CbGpPWpGaD
Naloxone—ALB—Metabolism—ABCC8—type 1 diabetes mellitus	4.96e-05	0.000143	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GCG—type 1 diabetes mellitus	4.96e-05	0.000143	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	4.93e-05	0.000142	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—EGFR—type 1 diabetes mellitus	4.92e-05	0.000142	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	4.91e-05	0.000141	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SH2B3—type 1 diabetes mellitus	4.86e-05	0.00014	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—IL2—type 1 diabetes mellitus	4.84e-05	0.000139	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APOC3—type 1 diabetes mellitus	4.83e-05	0.000139	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IAPP—type 1 diabetes mellitus	4.83e-05	0.000139	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VAV1—type 1 diabetes mellitus	4.79e-05	0.000138	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—type 1 diabetes mellitus	4.77e-05	0.000137	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL10—type 1 diabetes mellitus	4.77e-05	0.000137	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VAV1—type 1 diabetes mellitus	4.77e-05	0.000137	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL10—type 1 diabetes mellitus	4.76e-05	0.000137	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD80—type 1 diabetes mellitus	4.71e-05	0.000136	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—type 1 diabetes mellitus	4.68e-05	0.000135	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCR5—type 1 diabetes mellitus	4.63e-05	0.000133	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ITPR3—type 1 diabetes mellitus	4.58e-05	0.000132	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2RA—type 1 diabetes mellitus	4.56e-05	0.000131	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS2—type 1 diabetes mellitus	4.48e-05	0.000129	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—GCG—type 1 diabetes mellitus	4.47e-05	0.000129	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—TYK2—type 1 diabetes mellitus	4.35e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Disease—CD80—type 1 diabetes mellitus	4.35e-05	0.000125	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ABCC8—type 1 diabetes mellitus	4.34e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—EGFR—type 1 diabetes mellitus	4.34e-05	0.000125	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—TYK2—type 1 diabetes mellitus	4.34e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF2—type 1 diabetes mellitus	4.33e-05	0.000125	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF2—type 1 diabetes mellitus	4.32e-05	0.000124	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SH2B3—type 1 diabetes mellitus	4.31e-05	0.000124	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	4.31e-05	0.000124	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOC3—type 1 diabetes mellitus	4.28e-05	0.000123	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IAPP—type 1 diabetes mellitus	4.28e-05	0.000123	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2RA—type 1 diabetes mellitus	4.26e-05	0.000123	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SST—type 1 diabetes mellitus	4.24e-05	0.000122	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—VDR—type 1 diabetes mellitus	4.24e-05	0.000122	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ADRB1—type 1 diabetes mellitus	4.22e-05	0.000122	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CAT—type 1 diabetes mellitus	4.19e-05	0.000121	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VAV1—type 1 diabetes mellitus	4.18e-05	0.00012	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CD86—type 1 diabetes mellitus	4.17e-05	0.00012	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL10—type 1 diabetes mellitus	4.17e-05	0.00012	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—EGFR—type 1 diabetes mellitus	4.17e-05	0.00012	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CD86—type 1 diabetes mellitus	4.16e-05	0.00012	CbGpPWpGaD
Naloxone—CREB1—Disease—INS—type 1 diabetes mellitus	4.11e-05	0.000118	CbGpPWpGaD
Naloxone—CREB1—Immune System—TYK2—type 1 diabetes mellitus	3.97e-05	0.000114	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—IL2—type 1 diabetes mellitus	3.97e-05	0.000114	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—E2F1—type 1 diabetes mellitus	3.96e-05	0.000114	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—E2F1—type 1 diabetes mellitus	3.95e-05	0.000114	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—KCNJ11—type 1 diabetes mellitus	3.94e-05	0.000114	CbGpPWpGaD
Naloxone—ALB—Metabolism—KCNJ11—type 1 diabetes mellitus	3.92e-05	0.000113	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—TYK2—type 1 diabetes mellitus	3.8e-05	0.00011	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF2—type 1 diabetes mellitus	3.79e-05	0.000109	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—GCG—type 1 diabetes mellitus	3.78e-05	0.000109	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—IL6—type 1 diabetes mellitus	3.78e-05	0.000109	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB3—type 1 diabetes mellitus	3.76e-05	0.000108	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SST—type 1 diabetes mellitus	3.76e-05	0.000108	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB3—type 1 diabetes mellitus	3.75e-05	0.000108	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ADRB1—type 1 diabetes mellitus	3.74e-05	0.000108	CbGpPWpGaD
Naloxone—CREB1—Immune System—IFNG—type 1 diabetes mellitus	3.72e-05	0.000107	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCR5—type 1 diabetes mellitus	3.7e-05	0.000107	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCR5—type 1 diabetes mellitus	3.69e-05	0.000106	CbGpPWpGaD
Naloxone—CREB1—Disease—TYK2—type 1 diabetes mellitus	3.67e-05	0.000106	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS2—type 1 diabetes mellitus	3.66e-05	0.000105	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	3.65e-05	0.000105	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CD86—type 1 diabetes mellitus	3.65e-05	0.000105	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—type 1 diabetes mellitus	3.64e-05	0.000105	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	3.64e-05	0.000105	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	3.64e-05	0.000105	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL2—type 1 diabetes mellitus	3.62e-05	0.000104	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL2—type 1 diabetes mellitus	3.61e-05	0.000104	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS3—type 1 diabetes mellitus	3.6e-05	0.000104	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD4—type 1 diabetes mellitus	3.59e-05	0.000104	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VAV1—type 1 diabetes mellitus	3.53e-05	0.000102	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL10—type 1 diabetes mellitus	3.53e-05	0.000102	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL2—type 1 diabetes mellitus	3.48e-05	0.0001	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 1 diabetes mellitus	3.47e-05	0.0001	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—E2F1—type 1 diabetes mellitus	3.46e-05	9.97e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—KCNJ11—type 1 diabetes mellitus	3.43e-05	9.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GCG—type 1 diabetes mellitus	3.35e-05	9.66e-05	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—type 1 diabetes mellitus	3.34e-05	9.61e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ITPR3—type 1 diabetes mellitus	3.33e-05	9.58e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1B—type 1 diabetes mellitus	3.32e-05	9.56e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—CD4—type 1 diabetes mellitus	3.32e-05	9.56e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ITPR3—type 1 diabetes mellitus	3.31e-05	9.53e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL2—type 1 diabetes mellitus	3.31e-05	9.53e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB3—type 1 diabetes mellitus	3.29e-05	9.47e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HBA2—type 1 diabetes mellitus	3.28e-05	9.46e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IGF1—type 1 diabetes mellitus	3.25e-05	9.35e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCR5—type 1 diabetes mellitus	3.23e-05	9.32e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PRKCQ—type 1 diabetes mellitus	3.23e-05	9.3e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—TYK2—type 1 diabetes mellitus	3.21e-05	9.26e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF2—type 1 diabetes mellitus	3.2e-05	9.22e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	3.19e-05	9.18e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL2—type 1 diabetes mellitus	3.16e-05	9.11e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VAV1—type 1 diabetes mellitus	3.13e-05	9.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HBA1—type 1 diabetes mellitus	3.13e-05	9.02e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL10—type 1 diabetes mellitus	3.13e-05	9e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—HBA1—type 1 diabetes mellitus	3.11e-05	8.97e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOC3—type 1 diabetes mellitus	3.11e-05	8.96e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOC3—type 1 diabetes mellitus	3.09e-05	8.91e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—G6PC2—type 1 diabetes mellitus	3.09e-05	8.89e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CD86—type 1 diabetes mellitus	3.08e-05	8.88e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTT1—type 1 diabetes mellitus	3.06e-05	8.8e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CD80—type 1 diabetes mellitus	3.04e-05	8.77e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTT1—type 1 diabetes mellitus	3.04e-05	8.75e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CD80—type 1 diabetes mellitus	3.03e-05	8.74e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2—type 1 diabetes mellitus	2.94e-05	8.48e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS3—type 1 diabetes mellitus	2.94e-05	8.48e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—E2F1—type 1 diabetes mellitus	2.93e-05	8.43e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ITPR3—type 1 diabetes mellitus	2.9e-05	8.35e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—INS—type 1 diabetes mellitus	2.88e-05	8.29e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—INS—type 1 diabetes mellitus	2.87e-05	8.26e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF2—type 1 diabetes mellitus	2.84e-05	8.18e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	2.82e-05	8.11e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—INS—type 1 diabetes mellitus	2.78e-05	8.02e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—STAT3—type 1 diabetes mellitus	2.78e-05	8.02e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.78e-05	8.01e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB3—type 1 diabetes mellitus	2.78e-05	8.01e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.77e-05	7.99e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EGFR—type 1 diabetes mellitus	2.77e-05	7.97e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EGFR—type 1 diabetes mellitus	2.76e-05	7.95e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCR5—type 1 diabetes mellitus	2.73e-05	7.88e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CD86—type 1 diabetes mellitus	2.73e-05	7.87e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HBA1—type 1 diabetes mellitus	2.73e-05	7.86e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOC3—type 1 diabetes mellitus	2.71e-05	7.81e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	2.69e-05	7.76e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCC8—type 1 diabetes mellitus	2.68e-05	7.71e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2—type 1 diabetes mellitus	2.67e-05	7.7e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTT1—type 1 diabetes mellitus	2.66e-05	7.67e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CD80—type 1 diabetes mellitus	2.66e-05	7.66e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—E2F1—type 1 diabetes mellitus	2.59e-05	7.47e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.57e-05	7.4e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—STAT3—type 1 diabetes mellitus	2.57e-05	7.4e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.56e-05	7.38e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ALB—type 1 diabetes mellitus	2.55e-05	7.35e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—type 1 diabetes mellitus	2.53e-05	7.29e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.52e-05	7.27e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.51e-05	7.24e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—INS—type 1 diabetes mellitus	2.51e-05	7.24e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—type 1 diabetes mellitus	2.49e-05	7.19e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB3—type 1 diabetes mellitus	2.46e-05	7.1e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NOS3—type 1 diabetes mellitus	2.44e-05	7.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GCG—type 1 diabetes mellitus	2.44e-05	7.01e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.43e-05	7e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCR5—type 1 diabetes mellitus	2.42e-05	6.98e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GCG—type 1 diabetes mellitus	2.42e-05	6.97e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—type 1 diabetes mellitus	2.42e-05	6.97e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	2.39e-05	6.88e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—type 1 diabetes mellitus	2.34e-05	6.73e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	2.33e-05	6.72e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CD80—type 1 diabetes mellitus	2.25e-05	6.48e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TYK2—type 1 diabetes mellitus	2.25e-05	6.47e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NOS3—type 1 diabetes mellitus	2.2e-05	6.35e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.14e-05	6.17e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—type 1 diabetes mellitus	2.14e-05	6.16e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP3—type 1 diabetes mellitus	2.13e-05	6.15e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—type 1 diabetes mellitus	2.13e-05	6.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—type 1 diabetes mellitus	2.13e-05	6.13e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—INS—type 1 diabetes mellitus	2.12e-05	6.12e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GCG—type 1 diabetes mellitus	2.12e-05	6.11e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—type 1 diabetes mellitus	2.12e-05	6.11e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—KCNJ11—type 1 diabetes mellitus	2.12e-05	6.09e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAT—type 1 diabetes mellitus	2.06e-05	5.94e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1—type 1 diabetes mellitus	2.06e-05	5.92e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAT—type 1 diabetes mellitus	2.05e-05	5.9e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—type 1 diabetes mellitus	2.04e-05	5.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CD80—type 1 diabetes mellitus	1.99e-05	5.74e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—type 1 diabetes mellitus	1.94e-05	5.6e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.9e-05	5.47e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—INS—type 1 diabetes mellitus	1.88e-05	5.43e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.87e-05	5.39e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—type 1 diabetes mellitus	1.87e-05	5.38e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.86e-05	5.37e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—type 1 diabetes mellitus	1.86e-05	5.36e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.82e-05	5.25e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.8e-05	5.18e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAT—type 1 diabetes mellitus	1.8e-05	5.17e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—type 1 diabetes mellitus	1.79e-05	5.17e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.79e-05	5.17e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ITPR3—type 1 diabetes mellitus	1.79e-05	5.14e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.68e-05	4.85e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HBA1—type 1 diabetes mellitus	1.68e-05	4.84e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOC3—type 1 diabetes mellitus	1.67e-05	4.81e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.65e-05	4.76e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—type 1 diabetes mellitus	1.64e-05	4.73e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.64e-05	4.71e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.63e-05	4.7e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.58e-05	4.56e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—type 1 diabetes mellitus	1.58e-05	4.55e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.57e-05	4.53e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—type 1 diabetes mellitus	1.57e-05	4.53e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.43e-05	4.12e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.4e-05	4.04e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—type 1 diabetes mellitus	1.4e-05	4.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—INS—type 1 diabetes mellitus	1.37e-05	3.94e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—INS—type 1 diabetes mellitus	1.36e-05	3.92e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.33e-05	3.83e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GCG—type 1 diabetes mellitus	1.31e-05	3.77e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.26e-05	3.62e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—type 1 diabetes mellitus	1.25e-05	3.61e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.25e-05	3.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.21e-05	3.48e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—type 1 diabetes mellitus	1.2e-05	3.46e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—type 1 diabetes mellitus	1.19e-05	3.44e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—INS—type 1 diabetes mellitus	1.19e-05	3.43e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.18e-05	3.39e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAT—type 1 diabetes mellitus	1.11e-05	3.19e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.1e-05	3.16e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALB—type 1 diabetes mellitus	1.09e-05	3.15e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.07e-05	3.09e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—type 1 diabetes mellitus	1.05e-05	3.01e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—type 1 diabetes mellitus	9.28e-06	2.67e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—type 1 diabetes mellitus	8.23e-06	2.37e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—INS—type 1 diabetes mellitus	7.34e-06	2.12e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALB—type 1 diabetes mellitus	6.73e-06	1.94e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—type 1 diabetes mellitus	6.44e-06	1.86e-05	CbGpPWpGaD
